NCT04152499: A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced/Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies

NCT04152499
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with triple-negative breast cancer (TNBC) will be eligible for phase 2 of the study
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients previously treated with TROP 2 targeted therapies (e.g. datopotamab deruxtecan/Dato-DXd/DS-1062a, Trodelvy/sacituzumab govitecan)
https://ClinicalTrials.gov/show/NCT04152499

Comments are closed.

Up ↑